LYKALABS
Lyka Labs Limited (LYKALABS) Stock Analysis
Lyka Labs Limited is an Indian pharmaceutical company manufacturing formulations and APIs with a focus on niche therapies and contract manufacturing. It supplies domestic and export markets from regulated plants. The business competes in India's generic pharmaceutical industry. It is listed on Indian stock exchanges.
Healthcare › Biotechnology
₹72.70
-10.91% 1W | -21.30% 52W
Market Cap
263 CR
P/E Ratio
–
52W High
₹100.9
52W Low
₹44.1
Div. Yield
0%
Beta
0.6
50 DMA
₹74.9
200 DMA
₹67.4
Profit Margin
-6.6%
Inst. Own.
0%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 22.88 | 27.99 | 32.56 | 27.77 | 30.11 | 41.16 | 33.80 | 33.43 | 33.03 | 36.66 | 30.73 | 28.03 | 42.31 |
| Expenses | 20.24 | 23.82 | 25.69 | 25.75 | 26.40 | 36.21 | 28.61 | 29.35 | 29.35 | 39.20 | 29.08 | 34.48 | 37.76 |
| Operating Profit | 2.64 | 4.17 | 6.87 | 2.02 | 3.71 | 4.95 | 5.19 | 4.08 | 3.68 | -2.54 | 1.65 | -6.45 | 4.55 |
| OPM % | 11.54% | 14.90% | 21.10% | 7.27% | 12.32% | 12.03% | 15.36% | 12.20% | 11.14% | -6.93% | 5.37% | -23.01% | 10.75% |
| Other Income | 0.38 | -0.18 | 0.54 | 0.32 | 0.56 | 0.03 | 0.83 | 0.82 | 0.63 | 1.09 | 1.16 | 0.61 | 0.42 |
| Interest | 1.35 | 1.19 | 1.28 | 1.07 | 0.65 | 0.54 | 0.61 | 0.47 | 0.85 | 0.79 | 0.82 | 0.70 | 1.01 |
| Depreciation | 3.47 | 3.59 | 2.84 | 2.90 | 1.76 | 1.76 | 1.83 | 1.42 | 2.11 | 2.15 | 2.15 | 2.04 | 2.01 |
| Profit before tax | -1.80 | -0.79 | 3.29 | -1.63 | 1.86 | 2.68 | 3.58 | 3.01 | 1.35 | -4.39 | -0.16 | -8.58 | 1.95 |
| Tax % | 7.22% | -22.78% | 38.60% | 28.22% | 30.65% | 28.36% | 24.30% | 32.89% | 26.67% | -26.65% | -6.25% | -6.06% | -5.13% |
| Net Profit | -1.85 | -0.49 | 1.78 | -2.09 | 1.29 | 1.91 | 2.70 | 2.03 | 0.99 | -3.22 | -0.15 | -8.07 | 2.05 |
| EPS in Rs | -0.56 | -0.15 | 0.54 | -0.63 | 0.40 | 0.59 | 0.76 | 0.50 | 0.26 | -0.94 | -0.00 | -2.13 | 0.57 |
| Metric | Jun 2015 | Mar 20169m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 166 | 130 | 110 | 60 | 71 | 61 | 86 | 194 | 93 | 111 | 138 | 128 | 138 |
| Expenses | 139 | 110 | 87 | 63 | 73 | 65 | 67 | 93 | 76 | 95 | 121 | 132 | 141 |
| Operating Profit | 28 | 20 | 23 | -4 | -2 | -4 | 20 | 101 | 17 | 16 | 18 | -3 | -3 |
| OPM % | 17% | 16% | 21% | -6% | -2.7% | -6% | 23% | 52% | 18% | 14% | 13% | -2.7% | -2.0% |
| Other Income | 4 | 8 | -2 | 4 | 1 | -30 | 0 | -4 | -4 | 1 | 2 | 4 | 3 |
| Interest | 24 | 15 | 19 | 10 | 7 | 20 | 26 | 20 | 12 | 5 | 2 | 3 | 3 |
| Depreciation | 11 | 9 | 10 | 11 | 7 | 8 | 8 | 17 | 14 | 13 | 7 | 8 | 8 |
| Profit before tax | -3 | 4 | -8 | -20 | -15 | -62 | -14 | 59 | -13 | -1 | 11 | -12 | -11 |
| Tax % | 31% | -5% | -19% | -5% | -59% | 1% | -29% | 35% | -0% | 182% | 29% | -11% | |
| Net Profit | -5 | 4 | -7 | -19 | -6 | -63 | -10 | 38 | -13 | -3 | 8 | -10 | -9 |
| EPS in Rs | -2.29 | 1.67 | -2.51 | -6.14 | -1.97 | -21.10 | -4.03 | 13.59 | -4.30 | -0.75 | 2.24 | -2.81 | -2.50 |
| Dividend Payout % | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 11.0% | 8.0% | 0.0% |
| Profit CAGR | -32.0% | 1.0% | – |
Shareholding Pattern
Promoters58.16%
FIIs0.16%
DIIs0.66%
Public41.02%
Promoters58.16%
FIIs0.17%
DIIs0.66%
Public40.99%
Promoters58.16%
FIIs0.17%
DIIs0.66%
Public40.99%
Promoters58.16%
FIIs0.29%
DIIs0.66%
Public40.89%
Promoters58.45%
FIIs0.17%
DIIs0.66%
Public40.73%
Promoters51.00%
FIIs0.18%
DIIs3.74%
Public45.08%
Promoters54.81%
FIIs0.17%
DIIs0.81%
Public44.21%
Promoters58.16%
FIIs0.24%
DIIs0.66%
Public40.93%
Promoters58.16%
FIIs0.29%
DIIs0.66%
Public40.89%
Promoters58.45%
FIIs0.17%
DIIs0.66%
Public40.73%
LYKALABS
Holdings Analysis
Key strengths & risk signals
50
Overall
37
Fundamental
64
Technical
Risks (4)
Cannot calculate PEG - insufficient growth data.
POOR YEAR! Stock declined 21.3% in the last year.
RECOVERY MODE! Current price (72.7) above 200-day but below 50-day.
WEAK MOMENTUM! Limited price growth - -10.9% (1 week), -12.6% (1 month), 2.3% (3 months).
Strengths (3)
BULLISH TREND! 50-day average (74.9) is above 200-day average (67.4) - positive signal.
LOW VOLATILITY! Beta of 0.60 - stable stock, less market risk.
BULLISH SENTIMENT! In last 30 days: 15 up days, 15 down days. Avg volume on up days: 23,736 vs down days: 16,658. Ratio: 1.42x
Fundamental & Technical Analysis
50Overall
37Fundamental
64Technical
Fundamental Breakdown
Growth Quality
13/30
Revenue CAGR: 13.3% (GOOD, 11/15). Profit CAGR: 0% (DECLINING, 2/15).
Profit Margin
2/10
LOW MARGIN! -6.6% profit margin - thin profits.
PEG Valuation
0/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
5/20
TOO MUCH PUBLIC HOLDING! 44.84% public ownership - higher volatility risk.
Stability Index
4/10
CAREFUL! Company does not have stable profit track. 2 loss-making quarters detected.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (74.9) is above 200-day average (67.4) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (72.7) above 200-day but below 50-day.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
1/10
POOR YEAR! Stock declined 21.3% in the last year.
Volume Sentiment
25/30
BULLISH SENTIMENT! In last 30 days: 15 up days, 15 down days. Avg volume on up days: 23,736 vs down days: 16,658. Ratio: 1.42x
RSI
4/5
APPROACHING OVERSOLD! RSI at 34.8 - watch for reversal.
52W Range
3/5
MID RANGE! Trading at 50.4% of 52W range - neutral zone.
Momentum
2/5
WEAK MOMENTUM! Limited price growth - -10.9% (1 week), -12.6% (1 month), 2.3% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.60 - stable stock, less market risk.
Peer Comparison
Healthcare · Biotechnology · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LYKALABS | ₹72.70 | – | -6.6% | 13.3% | – | -21.3% | 50 | BREAKDOWN | +133.3% | -127.6% | +28.2% | +51.1% |
| HALEOSLABS | ₹1,563.70 | 29.9 | 4.9% | 0.3% | 14.7% | +41.6% | 69 | BREAKOUT | -38.1% | +550.0% | -11.6% | -2.9% |
| PANACEABIO | ₹345.20 | – | -1.1% | 10.1% | – | -17.9% | 49 | BOUNCE FROM SUPPORT | -42.5% | +360.0% | +19.7% | +19.7% |
| DCAL | ₹149.70 | 145.3 | 0.6% | 9.0% | 21.0% | -50.1% | 55 | BOUNCE FROM SUPPORT | -347.9% | -367.3% | -4.2% | -20.4% |
| ZOTA | ₹1,324.10 | – | -17.0% | 56.7% | – | -7.9% | 57 | CONSOLIDATING UP | +204.9% | +207.0% | +67.6% | +6.4% |
| 3BBLACKBIO | ₹1,586.40 | 24.1 | 36.3% | 31.9% | 32.2% | +40.7% | 76 | CONSOLIDATING UP | -24.6% | -1.0% | +50.9% | -5.4% |
| SUPRIYA | ₹847.60 | 34.4 | 22.7% | 21.2% | 32.5% | +23.4% | 83 | BOUNCE FROM SUPPORT | -31.0% | -67.7% | +30.7% | -31.4% |
| BLUEJET | ₹514.60 | 38 | 26.5% | 9.4% | 15.7% | -17.2% | 73 | BOUNCE FROM SUPPORT | -14.1% | +21.8% | -17.4% | +24.9% |
Data from TradeAlone · Updated daily
No news tagged for LYKALABS yet.
